Based on the recent insights into the prognostic roles of immunonutrition and CRP for patients with HCC undergoing TACE, the combination of these markers and their evaluation seemed to be the next step for advancing the field [18,44]. This evidence concerns the gene CRP and hepatocellular carcinoma.